Compositions of PD-1 antagonists and methods of use

Details for Australian Patent Application No. 2009288730 (hide)

Owner Amplimmune, Inc.

Inventors Langerman, Solomon

Agent Davies Collison Cave

Pub. Number AU-A-2009288730

PCT Pub. Number WO2010/027423

Priority 61/091,709 25.08.08 US; 61/091,694 25.08.08 US; 61/091,705 25.08.08 US; 61/211,697 02.04.09 US

Filing date 25 August 2009

Wipo publication date 11 March 2010

International Classifications

C07K 16/00 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 14/00 (2006.01) Peptides having more than 20 amino acids

Event Publications

10 March 2011 PCT application entered the National Phase

  PCT publication WO2010/027423 Priority application(s): WO2010/027423

16 June 2011 Amendment Made

  The nature of the amendment is: Amend the name of the inventor to read Langerman, Solomon and Liu, Linda

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009288738-Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders

2009288728-Determining electric grid endpoint phase connectivity